UroGen Pharma Ltd. Shareholders' Equity
UroGen Pharma Ltd. (URGN) had Shareholders' Equity of -$132.40 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent -$132.40M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$124.25M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$105.47M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$115.41M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$132.40M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$124.25M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | -$105.47M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | -$115.41M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$93.38M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | -$46.46M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | -$8.80M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $25.52M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $30.31M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | -$40.13M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | -$65.21M 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$41.99M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$138.43M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | -$116.55M 10-Q · filed 2024-08-13 | |
| 2022-12-31 | -$89.36M 10-K · filed 2025-03-10 | |
| 2022-09-30 | -$63.29M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$40.91M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | -$17.07M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $8.41M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $31.54M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $56.27M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $76.49M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $96.36M 10-K · filed 2023-03-24 | |
| 2020-09-30 | $120.53M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $142.66M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $150.45M 10-Q · filed 2021-08-04 | |
| 2019-12-31 | $180.30M 10-K · filed 2022-03-21 | |
| 2019-09-30 | $210.92M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $224.78M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $239.59M 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $90.09M 10-K · filed 2021-03-18 | |
| 2018-09-30 | $103.58M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $113.55M 10-Q · filed 2019-11-12 | $113.55M 6-K · filed 2018-08-14 |
| 2018-03-31 | $123.87M 10-Q · filed 2019-08-09 | |
| 2017-12-31 | $68.52M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $76.26M 6-K · filed 2018-11-13 | |
| 2017-06-30 | $74.07M 6-K · filed 2018-08-14 | |
| 2017-03-31 | $13.19M 6-K · filed 2018-05-15 | |
| 2016-12-31 | $16.31M 10-K · filed 2020-03-02 | |
| 2015-12-31 | $16.28M 10-K · filed 2019-02-28 | |
| 2014-12-31 | $3.16M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |